A phase II single‐arm trial of memantine for prevention of cognitive decline during chemotherapy in patients with early breast cancer: Feasibility, tolerability, acceptability, and preliminary effects

BACKGROUND: Cognitive difficulties have been described after chemotherapy for breast cancer, but there is no standard of care to improve cognitive outcomes in these patients. This trial examined the feasibility, tolerability, acceptability, and preliminary effects of memantine to prevent cognitive d...

Descripción completa

Detalles Bibliográficos
Autores principales: Nakamura, Zev M., Deal, Allison M., Park, Eliza M., Stanton, Kate E., Lopez, Yesy E., Quillen, Laura J., O’Hare Kelly, Erin, Heiling, Hillary M., Nyrop, Kirsten A., Ray, Emily M., Dees, E. Claire, Reeder‐Hayes, Katherine E., Jolly, Trevor A., Carey, Lisa A., Abdou, Yara, Olajide, Oludamilola A., Rauch, Julia K., Joseph, Ranjit, Copeland, Anureet, McNamara, Megan A., Ahles, Tim A., Muss, Hyman B.
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2023
Materias:
RESEARCH ARTICLES
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134315/
https://www.ncbi.nlm.nih.gov/pubmed/36645168
http://dx.doi.org/10.1002/cam4.5619

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC10134315/
https://www.ncbi.nlm.nih.gov/pubmed/36645168
http://dx.doi.org/10.1002/cam4.5619

Ejemplares similares